The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 23, 2021

Filed:

Jan. 15, 2019
Applicant:

Humanigen, Inc., Burlingame, CA (US);

Inventors:

Cameron Durrant, Oxford, FL (US);

Dale Chappell, Nidwalden, CH;

Assignee:

HUMANICEN, INC., Burlingame, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); A61K 35/17 (2015.01);
U.S. Cl.
CPC ...
C07K 16/243 (2013.01); A61K 35/17 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01);
Abstract

Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having an incidence of immunotherapy-related toxicity, the methods comprising administering a recombinant GM-CSF antagonist to the subject. Methods for treating or preventing immunotherapy-related toxicity in a subject, the methods comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSFCAR-T cells), and a recombinant hGM-CSF antagonist.


Find Patent Forward Citations

Loading…